Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Corvus Pharma Com (CRVS)

Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,341,126
  • Shares Outstanding, K 83,768
  • Annual Sales, $ 0 K
  • Annual Income, $ -62,290 K
  • EBIT $ -39 M
  • EBITDA $ -40 M
  • 60-Month Beta 0.78
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 17.42

Options Overview Details

View History
  • Implied Volatility 91.08% (-0.52%)
  • Historical Volatility 63.27%
  • IV Percentile 40%
  • IV Rank 6.07%
  • IV High 320.47% on 04/10/25
  • IV Low 76.25% on 01/23/26
  • Expected Move (DTE 7) 1.83 (11.41%)
  • Put/Call Vol Ratio 0.17
  • Today's Volume 920
  • Volume Avg (30-Day) 1,258
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 39,250
  • Open Int (30-Day) 42,450
  • Expected Range 14.18 to 17.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.14
  • Number of Estimates 2
  • High Estimate -0.13
  • Low Estimate -0.15
  • Prior Year -0.13
  • Growth Rate Est. (year over year) -7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.38 +4.10%
on 03/06/26
19.98 -19.87%
on 02/13/26
-2.75 (-14.66%)
since 02/12/26
3-Month
6.39 +150.55%
on 01/12/26
26.95 -40.59%
on 01/23/26
+7.64 (+91.28%)
since 12/12/25
52-Week
2.54 +530.32%
on 04/09/25
26.95 -40.59%
on 01/23/26
+11.38 (+245.79%)
since 03/12/25

Most Recent Stories

More News
Corvus: Q4 Earnings Snapshot

Corvus: Q4 Earnings Snapshot

CRVS : 16.01 (-5.27%)
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiated...

CRVS : 16.01 (-5.27%)
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference...

CRVS : 16.01 (-5.27%)
Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership...

CRVS : 16.01 (-5.27%)
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026

Three standout stocks for 2026 have already generated massive returns of 56% or more this year, although they may cater to investors with a tolerance for risk.

CRVS : 16.01 (-5.27%)
USAR : 19.75 (-6.35%)
NUAI : 4.92 (-6.46%)
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underwritten...

CRVS : 16.01 (-5.27%)
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an upsized underwritten...

CRVS : 16.01 (-5.27%)
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten...

CRVS : 16.01 (-5.27%)
Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following longer 8-week treatment  75% of soquelitinib patients achieved EASI 75, 25%...

CRVS : 16.01 (-5.27%)
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced that it will host a conference call and...

CRVS : 16.01 (-5.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible...

See More

Key Turning Points

3rd Resistance Point 17.77
2nd Resistance Point 17.22
1st Resistance Point 16.61
Last Price 16.01
1st Support Level 15.45
2nd Support Level 14.90
3rd Support Level 14.29

See More

52-Week High 26.95
Fibonacci 61.8% 17.63
Last Price 16.01
Fibonacci 50% 14.75
Fibonacci 38.2% 11.86
52-Week Low 2.54

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar